Skip to main content
FARON PHARMACEUTICALS OY logo

FARON PHARMACEUTICALS OY — Investor Relations & Filings

Ticker · FARN ISIN · FI4000153309 LEI · 7437009H31TO1DC0EB42 IL Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2026-03-31 Director's Dealing
Country FI Finland
Listing IL FARN

About FARON PHARMACEUTICALS OY

https://faron.com/

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.

Recent filings

Filing Released Lang Actions
Faron Pharmaceuticals Ltd: Director Dealing
Director's Dealing Classification · 95% confidence The document is a company announcement titled “Faron Pharmaceuticals Ltd: Director Dealing.” It contains the standard Notification of Dealing form under Article 19(1) of Regulation (EU) No. 596/2014, detailing an insider transaction by Tuomo Pätsi (Non-Executive Chairman). This is precisely a report of personal share transactions by a company director, matching the Director’s Dealing category.
2026-03-31 English
Faron Pharmaceuticals Ltd: Faron appoints new CTO to strengthen late-stage development activities
Board/Management Information Classification · 90% confidence The document is a company announcement from Faron Pharmaceuticals announcing the appointment of a new Chief Technical Officer, which is a senior management change. This fits the Board/Management Information category (MANG).
2026-03-26 English
Faron Pharmaceuticals Ltd: Director Dealing
Director's Dealing Classification · 95% confidence The document is a company announcement detailing a personal share transaction by a person closely associated with a board member, including a MAR Article 19 notification form. This fits the definition of a Director's Dealing report.
2026-03-25 English
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Major Shareholding Notification Classification · 95% confidence The document is a TR-1 “Standard form for notification of major holdings” indicating the crossing of a voting rights threshold and detailing the percentage of voting rights held. This matches the definition of a Major Shareholding Notification. Therefore, the correct classification is MRQ.
2026-03-24 English
Faron Pharmaceuticals Ltd: Director Dealing
Director's Dealing Classification · 100% confidence The document is a formal announcement regarding share subscriptions by the CEO and persons closely associated with him. It explicitly includes a 'Notification of a Transaction' table pursuant to Article 19(1) of the EU Market Abuse Regulation (MAR), which is the standard regulatory format for reporting insider/director dealings. Therefore, it is classified as a Director's Dealing.
2026-03-19 English
Faron Pharmaceuticals Ltd: Director Dealing
Director's Dealing Classification · 100% confidence The document is titled 'Director Dealing' and explicitly details a share acquisition by a senior manager (Yrjö Wichmann) of Faron Pharmaceuticals. It includes the required 'Notification of a Transaction' table pursuant to Article 19(1) of Regulation (EU) No. 596/2014 (MAR), which is the standard format for reporting insider/director transactions. This fits the definition of 'Director's Dealing' (DIRS).
2026-03-19 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.